Cover Image

Abstract

The cover image, by S. R. Shah et al., is based on the Original Article Sofosbuvir plus ribavirin in treatment‐naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India, DOI .

Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug

“…Sofosbuvir is currently used for HCV treatment since the FDA approved it in 2013 (Gane et al, 2013). The safety profile of Sofosbuvir was tested over millions of people worldwide and different companies are manufacturing it at affordable prices in low-income countries like India and Egypt (Omar et al, 2018;Elsharkawy et al, 2017;Shah et al, 2017). Sofosbuvir is able to bind to RdRp of SARS-CoV-2 with comparable binding energies compared to Remdesivir (Fig.…”